FORM 4

# **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB	APP	RO\	/AI

	OMB Number:	3235-0287
	Estimated average burden	
-1	l <b>.</b>	0.5

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

10b5-1(c). See Inst	ruction 10.				
1. Name and Address of Reporting Person * <u>Lalezari Jacob P</u>		son*	2. Issuer Name <b>and</b> Ticker or Trading Symbol  CytoDyn Inc. [ CYDY ]	5. Relationship of Rep (Check all applicable)	orting Person(s) to Issuer
(Last) 1111 MAIN STR	(First) EET, SUITE 66	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 10/28/2024	X Officer (give below)	
(Street)  VANCOUVER  (City)	WA (State)	98660 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	X Form filed b	roup Filing (Check Applicable Line) y One Reporting Person y More than One Reporting Person

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (Ir 8)	tion	4. Securities Ad Disposed Of (D			Securities Beneficially Owned Following Reported	 Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)	(Instr. 4)	

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following	Form: Direct (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)		
Non-qualified stock option (right to buy)	\$0.13	10/28/2024		A		3,000,000 <sup>(1)</sup>		(2)	10/28/2034	Common Stock	3,000,000	\$0	3,000,000	D	

# Explanation of Responses:

- 1. This grant was approved by the Company's Compensation Committee on October 28, 2024 and represents the annual grant awarded to the individual for fiscal year 2025. This award is made consistent with, and utilizes shares from, the Issuer's 2012 Equity Incentive Plan, as amended.
- 2. 250,000 shares vested on the grant date, and the balance will vest in equal monthly installments at the conclusion of each month of Continuous Service (as the term is defined in the Issuer's 2012 Equity Incentive Plan, as amended) from October 2024 through May 2028.

/s/ Tyler Blok, attorney-in-fact for Jacob P. Lalezari 10/30/2024

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.